Jump to main content
eTG Complete
eTG Complete
Index
  1. Home
  2. Cardiovascular
  3. Venous thromboembolism

  4. Venous thromboembolism (VTE) prophylaxis
  5. Parenteral anticoagulants for VTE prophylaxis
  6. Danaparoid for VTE prophylaxis
  • Cardiovascular
    • Atherosclerotic cardiovascular disease risk estimation
    • Modifiable lifestyle risk factors for atherosclerotic cardiovascular disease

    • Lipid modification
    • Blood pressure reduction

    • Acute chest pain of possible cardiac origin
    • Acute coronary syndromes

    • Stable angina
    • Antithrombotic therapy after endovascular and cardiac interventions
    • Secondary prevention of atherosclerotic cardiovascular events
    • Peripheral artery disease
    • Pericarditis
    • Heart failure

    • Cardiac rehabilitation programs
    • Tachyarrhythmias

    • Bradyarrhythmias
    • Orthostatic hypotension
    • Pulmonary hypertension
    • Venous thromboembolism

      • Venous thromboembolism (VTE) prophylaxis
        • Overview of VTE prophylaxis
        • Risk factors for VTE
        • Approach to VTE prophylaxis
        • Parenteral anticoagulants for VTE prophylaxis
          • Low molecular weight heparin for VTE prophylaxis
          • Unfractionated heparin for VTE prophylaxis
          • Fondaparinux for VTE prophylaxis
          • Danaparoid for VTE prophylaxis
        • Direct-acting oral anticoagulants for VTE prophylaxis
        • Aspirin for VTE prophylaxis following total hip or knee replacement
        • Mechanical VTE prophylaxis
        • VTE prophylaxis for nonsurgical patients
        • VTE prophylaxis for surgical patients
        • VTE prophylaxis for lower-limb immobilisation
        • VTE prophylaxis for long-distance travel
        • VTE prophylaxis during pregnancy and the postpartum period
        • VTE prophylaxis for patients with active cancer
        • References
      • Venous thromboembolism (VTE) treatment
    • Periprocedural management of patients with cardiovascular disease
    • Principles of anticoagulant therapy

Danaparoid for VTE prophylaxis

Danaparoid is approved for VTE prophylaxis for up to 10 days after total hip replacement or hip fracture surgery; for dosage, see the danaparoid product information. It is not widely used (except in patients with a history of heparin-induced thrombocytopenia [HIT]).

  • Contact us
  • Conditions of use and disclaimer
  • Privacy policy
  • Copyright permission
  • Support and FAQ

www.tg.org.au
All site content © Therapeutic Guidelines Limited 2020. Therapeutic Guidelines Limited, Ground Floor, 473 Victoria Street, West Melbourne, Victoria 3003, Australia © Therapeutic Guidelines Ltd (eTG August 2020)